As highlighted in Nature Reviews Nephrology by Prof. John Kellum (Center for Critical Care Nephrology, Univ. of Pittsburgh) in his review of progress in the field of Acute Kidney Injury (AKI) in 2018, mitochondrial dysfunction is a critical event that underlies AKI pathophysiology.

Approaches that restore mitochondrial function, including TES Pharma’s small molecule ACMSD inhibitors, reported in 2018 in both Nature and J. Med. Chem., are therefore important new therapeutic opportunities for the treatment of Acute Kidney Injury (AKI). ACMSD inhibition is a leading candidate for a disease-modifying therapy in this important area of critical care which currently lacks effective protective therapies.